Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock C fund, which has shown significant growth in recent months and years [1][3]. - As of August 22, 2025, the latest net value of ICBC Frontier Medical Stock C is 3.4340 yuan, reflecting a growth of 0.53% [1]. - The fund's performance over the past month has yielded a return of 4.66%, ranking 800 out of 1018 in its category [1]. - Over the last six months, the fund has achieved a return of 28.81%, ranking 124 out of 975 [1]. - Year-to-date, the fund has delivered a return of 33.72%, ranking 238 out of 965 [1]. - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%) and Kelun Pharmaceutical (9.16%) [1]. Group 2 - The ICBC Frontier Medical Stock C fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1]. - The fund manager, Zhao Bei, has extensive experience in the healthcare sector, having held various positions since joining ICBC Credit Suisse in 2010 [2]. - Zhao Bei has been managing the ICBC Healthcare Industry Equity Fund since November 18, 2014, and has also managed other funds related to healthcare and technology innovation [2].

Core Insights - The latest net value of ICBC Frontier Medical Stock C (010685) is 3.4160 yuan, reflecting a growth of 1.04% [1] - The fund has shown a monthly return of 3.83%, a six-month return of 28.13%, and a year-to-date return of 33.02% [1] - The fund's top ten stock holdings account for a total of 59.44%, with significant positions in companies such as Heng Rui Medicine (9.51%) and Ke Lun Pharmaceutical (9.16%) [1] Fund Performance - The fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2] Holdings Overview - The top ten holdings include: - Heng Rui Medicine: 9.51% - Ke Lun Pharmaceutical: 9.16% - Xin Li Tai: 6.70% - Hai Si Ke: 6.02% - Bai Ji Shen Zhou-U: 5.96% - Xin Nuo Wei: 5.86% - Ze Jing Pharmaceutical-U: 4.77% - Yao Ming Kang De: 4.60% - Hua Dong Medicine: 4.57% - Rong Chang Biological: 2.29% [1]

金融界2025年8月15日消息，工银前沿医疗股票C(010685) 最新净值3.4310元，增长1.21%。该基金近1个 月收益率8.68%，同类排名324|1030；近6个月收益率32.52%，同类排名93|993；今年来收益率33.61%， 同类排名140|983。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 来源：金融界 工银前沿医疗股票C股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9 ...

来源：金融界 公开资料显示，工银前沿医疗股票C基金成立于2020年11月23日，截至2025年6月30日，工银前沿医疗 股票C规模12.60亿元，基金经理为赵蓓。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 金融界2025年8月13日消息，工银前沿医疗股票C(010685) 最新净值3.3930元，增长3.13%。该基金近1个 月收益率10.74%，同类排名440|1030；近6个月收益率32.90%，同类排名91|993； ...

金融界2025年8月12日消息，工银前沿医疗股票C(010685) 最新净值3.2900元，下跌0.81%。该基金近1个 月收益率7.38%，同类排名279|656；近6个月收益率28.87%，同类排名62|637；今年来收益率28.12%， 同类排名105|635。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 工银前沿医疗股票C股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9.16%）、信立 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock C fund, which has shown significant returns over various time frames [1] - As of August 1, 2025, the latest net value of the fund is 3.3630 yuan, reflecting a decrease of 0.65% [1] - The fund's one-month return is 9.79%, ranking 170 out of 1031 in its category; the six-month return is 32.87%, ranking 84 out of 992; and the year-to-date return is 30.96%, ranking 103 out of 982 [1] Group 2 - The top ten holdings of the ICBC Frontier Medical Stock C fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%) and Kelun Pharmaceutical (9.16%) [1] - The fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector and has been managing this fund since February 3, 2016 [2]

Group 1 - The core point of the article highlights the performance and holdings of the Industrial Bank's Frontier Medical Stock C fund, which has shown significant returns over various time frames [1] - As of July 30, 2025, the latest net value of the fund is 3.3890 yuan, reflecting a decrease of 0.73%. The fund's one-month return is 14.49%, six-month return is 33.90%, and year-to-date return is 31.97% [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xinli Tai (6.70%) [1] Group 2 - The Industrial Bank's Frontier Medical Stock C fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1] - Zhao Bei serves as the fund manager and has extensive experience in the healthcare sector, having held various positions within the Industrial Bank since 2010 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock C fund, which has shown significant returns over various time frames [1] - As of July 23, 2025, the latest net value of the fund is 3.2590 yuan, reflecting a decrease of 0.67% [1] - The fund's one-month return is 9.99%, ranking 348 out of 1027 in its category; the six-month return is 29.58%, ranking 104 out of 995; and the year-to-date return is 26.91%, ranking 122 out of 989 [1] Group 2 - The top ten holdings of the ICBC Frontier Medical Stock C fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%) and Ke Lun Pharmaceutical (9.16%) [1] - The fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector and has been managing this fund since February 3, 2016 [2]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock C fund, which has a latest net value of 2.9480 yuan, reflecting a decrease of 1.54% [1] - The fund's one-month return is 2.47%, ranking 550 out of 932 in its category; the six-month return is 13.21%, ranking 130 out of 909; and the year-to-date return is 14.80%, ranking 127 out of 910 [1] - The top ten stock holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The ICBC Frontier Medical Stock C fund was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan [1] - Zhao Bei serves as the fund manager and has extensive experience in the healthcare sector, having held various positions within ICBC Credit Suisse Asset Management since 2010 [2]

Group 1 - The core viewpoint of the news is that the ICBC Frontier Medical Stock C (010685) has experienced a decline of 1.24% on June 19, with a cumulative drop of 8.33% over the last five trading days, and its latest net value is 2.94 yuan [1] - The fund was established in November 2020, with a total fund size of 1.38 billion yuan, and has recorded a cumulative return of -10.43% since inception [1] - As of the end of 2024, institutional investors hold 0.20 million shares, accounting for 3.55% of the total shares, while individual investors hold 5.51 million shares, making up 96.45% of the total [1] Group 2 - The current fund manager, Zhao Bei, has a master's degree and has been with ICBC Credit Suisse since 2010, currently serving as the deputy director of the research department and head of the healthcare research team [2] - Zhao has managed several funds, including the ICBC Healthcare Industry Stock Fund since November 2014 and the ICBC Frontier Medical Stock Fund since February 2016 [2] - As of March 31, 2025, the top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05%, with major holdings including Heng Rui Medicine (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [2]